The Technical Analyst
LogicBio Therapeutics, [LOGC]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
LogicBio Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $2.07
/ 15 nov 2022 @ 16:00
| RATING 2022-11-16 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.855 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -1.855 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.01 - 2.13 ( +/- 2.71%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-11-16 | Kay Mark A | Sell | 12 500 | Stock Option (right to buy) |
| 2022-11-16 | Enyedy Mark J | Sell | 12 500 | Stock Option (right to buy) |
| 2022-11-16 | Nacht Mariana | Sell | 100 000 | Stock Option (right to buy) |
| 2022-11-16 | Wyzga Michael S | Sell | 12 500 | Stock Option (right to buy) |
| 2022-11-16 | Chereau Frederic | Sell | 328 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| -88.76 |
| Last 94 transactions |
| Buy: 5 628 346 | Sell: 1 216 285 |
Forecast:
01:40 - $1.974
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.07 (0.00% ) |
| Volume | 0.153 mill |
| Avg. Vol. | 0.566 mill |
| % of Avg. Vol | 27.01 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For LOGC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
LOGC
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. As of November 15, 2022, LogicBio Therapeutics, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc..
Latest Press Releases
2022-03-23 16:30:00 - Press Release
Logicbio Therapeutics To Present At H.c. Wainwright Gene Therapy And Gene Editing Conference
Lexington, mass. , march 23, 2022 /prnewswire/ -- logicbio ® therapeutics, inc. (nasdaq: logc), a clinical-stage genetic medicine company, today announced that president and chief executive officer, frederic chereau, will present a company overview at the h.c.
2021-09-24 16:05:00 - Press Release
Logicbio Therapeutics To Participate In The 2021 Cantor Virtual Global Healthcare Conference
Lexington, mass., sept. 24, 2021 /prnewswire/ -- logicbio therapeutics, inc. (nasdaq:logc), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that president and chief executive officer, fred chereau, will participate in a fireside chat at the 2021 cantor virtual global healthcare conference on wednesday, september 29, 2021 at 8:00 a.m.
2021-09-10 08:00:00 - Press Release
Logicbio Therapeutics To Present At The H.c. Wainwright 23rd Annual Global Investment Conference
Lexington, mass., sept. 10, 2021 /prnewswire/ -- logicbio therapeutics, inc. (nasdaq:logc), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that president and chief executive officer fred chereau will present a company overview at the h.c.
2021-07-08 07:00:00 - Press Release
Logicbio Therapeutics To Participate In William Blair Biotech Focus Conference 2021
Lexington, mass., july 8, 2021 /prnewswire/ -- logicbio therapeutics, inc. (nasdaq:logc), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that frederic chereau, chief executive officer of logicbio, will participate in a virtual panel discussion entitled "delivery and durability of genetic medicines" at the william blair biotech focus conference 2021 on thursday, july 15, 2021 at 10:00 a.m.
2021-06-02 07:00:00 - Press Release
Logicbio Therapeutics Announces First Patient Dosed In Groundbreaking Phase 1/2 Sunrise Clinical Trial For The Treatment Of Pediatric Patients Suffering From Methylmalonic Acidemia
Lexington, mass., june 2, 2021 /prnewswire/ -- logicbio therapeutics, inc. (nasdaq:logc), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that the first patient has been dosed with lb-001, the company's investigational single-administration gene editing therapy based on its proprietary generide™ platform, in the sunrise phase 1/2 clinical trial in pediatric patients with methylmalonic acidemia (mma).
Latest News
2022-10-03 10:33:42 - InvestorPlace
Why Is LogicBio (LOGC) Stock Up 600% Today?
Source: Roland Magnusson / Shutterstock.com LogicBio (NASDAQ: LOGC ) stock is seeing massive gains on Monday following news that AstraZeneca (NASDAQ: AZN ) subsidiary Alexion is acquiring the clinical-stage genetic medicine company. The deal has Alexion agreeing to a cash tender offer for all outstanding shares of LOGC stock.
2022-10-03 09:27:43 - Pulse2
Why AstraZeneca (AZN) Is Buying LogicBio Therapeutics (LOGC) In About A $68 Million Deal
LogicBio Therapeutics, Inc. (LOGC) announced it is being acquired in a deal valued at about $68 million. These are the details.
2022-09-27 09:47:13 - Zacks Investment Research
5 Big Winners as Dollar Strengthens on Fed Rate Hike
A stronger dollar is a boon for Consolidated Water (CWCO), Ashford Hospitality Trust (AHT), BankFinancial (BFIN), LogicBio Therapeutics (LOGC) and ProPhase Labs (PRPH) that have high domestic exposure in terms of revenue generation.
2022-09-27 09:02:12 - Zacks Investment Research
5 Winning Stocks Backed by the Overlooked Trick of Rising P/E
Want to try an out-of-the-box approach? Tap Eastside Distilling (EAST), LogicBio Therapeutics (LOGC), Seabridge Gold (SA), Suzano (SUZ) and J Douglas Emmett (DEI).
2022-05-09 10:26:03 - Benzinga
Why LogicBio Therapeutics Shares Are Popping Off Today
LogicBio Therapeutics Inc (NASDAQ: LOGC) shares are trading higher by 63.48% at $0.81 after the company announced the FDA lifted the clinical hold on its LB-001 Investigational New Drug Application, allowing patient enrollment to resume in the Phase 1/2 SUNRISE trial for pediatric patients with.
2022-05-09 09:22:37 - PennyStocks
Stock Market Crash: 4 Penny Stocks To Watch As Dow Slides
Penny stocks to watch as stock market crash continues. The post Stock Market Crash: 4 Penny Stocks To Watch As Dow Slides appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-05-09 08:50:05 - Benzinga
LogicBio Therapeutics Shares Skyrocket As FDA Lifts Clinical Hold On Its Pediatric Trial
The FDA has lifted the clinical hold on LogicBio Therapeutics Inc's (NASDAQ: LOGC) LB-001 Investigational New Drug Application (IND) to resume patient enrollment in Phase 1/2 SUNRISE trial in pediatric methylmalonic acidemia patients. Methylmalonic acidemia is an.
2022-03-23 16:30:00 - PRNewsWire
LogicBio Therapeutics to Present at H.C. Wainwright Gene Therapy and Gene Editing Conference
LEXINGTON, Mass. , March 23, 2022 /PRNewswire/ -- LogicBio ® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will present a company overview at the H.C.
2022-02-02 12:34:44 - Benzinga
Why Did LogicBio Therapeutics Shares Plunge To 52-Week Low Today?
The FDA has placed a clinical hold on LogicBio Therapeutics Inc's (NASDAQ: LOGC) Phase 1/2 SUNRISE trial of LB-001 in pediatric patients with methylmalonic acidemia (MMA). The hold follows after two adolescent patients in the trial were diagnosed with thrombotic microangiopathy (TMA), a clinical syndrome defined by the formation of tiny clots in blood vessels.
2022-02-02 10:42:14 - Pulse2
LogicBio Therapeutics (LOGC): Why The Price Substantially Fell Today
The stock price LogicBio Therapeutics Inc (NASDAQ: LOGC) fell by over 50% during intraday trading today. This is why it happened.